Analysed REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ) News Sources
Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting
21-04-2026
yahoo.com
Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting
21-04-2026
yahoo.com
AACR 2026: Revolution’s next prospect, Merck’s reveal and a lung cancer battle
20-04-2026
biopharmadive.com
Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting
19-04-2026
yahoo.com
Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
17-04-2026
yahoo.com
Why Revolution Medicines (RVMD) Still Looks Like a Prime Takeover Target After Daraxonrasib Data
16-04-2026
yahoo.com
What is the current price of REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ)?
The current price of REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ) is $5.58.
REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ) absolute price change since previous trading day?
The absolute price change of REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ) since the previous trading day is $0.29.
REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ) percentage price change since previous trading day?
The percentage price change of REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ) since the previous trading day is 5.482%.
What is the most recent average sentiment score for REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ)?
The most recent average sentiment score for REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ) is 88 out of 100.
What is the most recent average sentiment for REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ)?
The most recent sentiment for REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ) is .
SEC-8K** Filing Available For REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.